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Jean-Louis Vincent1* and Daniel De Backer2Some of our colleagues believe that everything should be
tested in prospective, randomized clinical trials. Some of
our colleagues also believe that so-called pragmatic trials
can help improve the care of critically ill patients. The
designs of such studies are based on the postulate that
patients are all the same and will be globally either
improved or harmed by one strategy compared with
another. This may be true for some interventions but is
certainly not true for all, including choice of crystalloid
solution.
Saline versus balanced solutions
The difference between saline solutions and balanced
solutions is that saline solutions contain 154 mEq/L of
sodium and chloride (to be normotonic) and balanced
solutions contain anions other than chloride. Hence,
liberal administration of saline solutions results in hyper-
chloremia [1], which can have a number of unwanted
effects, including altered intrarenal hemodynamics
and perhaps coagulopathy and gastrointestinal symp-
toms [2, 3]. Without needing to review these effects
in detail, one can already see that any deviation of
any biological variable from the physiologic range of
values will be associated with a worse outcome. Why
would this be any different for chloride?
How do we prescribe fluids?
The choice of intravenous fluid should be based on
consideration of certain baseline factors, but also on
elements that arise during therapy. For example, at base-
line, administration of saline may be indicated in the
presence of hypochloremia whereas a hypotonic fluid
may be warranted in the presence of hypernatremia.
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ing to a different “best” fluid choice. Giving several liters
of 0.9 % saline will result in hyperchloremia, so continu-
ing this fluid strategy is not rational.Let us consider a clinical trial
Let us imagine a clinical trial in which saline is com-
pared with a balanced solution (Fig. 1). In the first
scenario (panel A), the saline solution is interrupted
when hyperchloremia begins to develop. In this scenario,
it is unlikely that any harm will be done and the study
will conclude that there was no significant difference in
outcomes between the two arms. The study will be criti-
cized on the basis that not enough saline was given to
the study population to be able to accurately assess the
effects of saline. Such an argument has been advanced
for the recently completed SPLIT study comparing saline
with Plasmalyte [4].
In scenario B, administration of saline solutions is
continued, regardless of the test results showing increas-
ing hyperchloremia. Here it is likely that the trial would
demonstrate worse outcomes in the saline arm. The
overall conclusion would be that saline solutions should
be banned or that hyperchloremia should be preven-
ted—these findings could have been predicted without
doing the trial! Moreover, the trial would be criticized as
it deviates from clinical practice.
Such a study may also have important “negative” clin-
ical and economic consequences. In scenario A, one can
argue that, with no differences between the study arms,
one should select the cheapest solution and abandon use
of costlier, balanced solutions, at least initially. This may
result in administration of large amounts of sodium
chloride, a condition that was not actually tested in the
trial. In scenario B, saline solutions may be banned
altogether and only balanced solutions used, thus unduly
increasing health care costs. And saline solutions may
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Fig. 1 The likely results from a hypothetical randomized clinical trial (RCT) comparing a saline solution with a balanced solution in critically ill
patients. Scenario A: saline solutions are discontinued as soon as hyperchloremia appears, thus preventing the harmful effects of a further increase
in chloremia and there will likely be no difference in outcomes in the two arms. Scenario B: the administration of saline solutions is continued
despite the development of hyperchloremia and the saline group will have worse outcomes than the balanced group
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bolic alkalosis.
The alternative
We rather propose improved education of the medical
community regarding the chemical composition of crys-
talloid solutions and better understanding of how solu-
tions should be selected depending on each patient’s
individual situation. We as clinicians should check blood
chloride levels exactly as we do sodium and potassium
levels and adapt our fluid choices accordingly.
The real issue for which a fluid trial could be of use is
to look at potential beneficial/detrimental effects of
added solutes, such as acetate, gluconate, and even
calcium or magnesium supplementation, but this would
require a particular design.
We should be pleased that we have the choice of sev-
eral different intravenous solutions, just as we are happy
to be able to have a choice of liquids to drink. Any pro-
spective, randomized controlled trial on different types
of oral fluid would certainly indicate that excessive
amounts of most drinks, especially when they contain al-
cohol, high sugar, or stimulants, are bad for the body.
This does not mean that we should only drink water.
But we should vary the types of liquid we drink and
drink all liquids in moderate, responsible amounts. Simi-
larly, we should not limit our intravenous fluid choices
to just one or two types and should not give any one
type in excess.
Undoubtedly, the safest intravenous solution in a pa-
tient without major metabolic abnormalities would havea composition close to that of human plasma. It has
been said that bicarbonate is unstable when in solution,
but this is not true as bicarbonate solutions are readily
available from the shelf; actually, renal substitution fluids
for continuous hemofiltration contain a mixture of elec-
trolytes, including bicarbonate. Some people already
administer these solutions as regular intravenous solu-
tions but the 5-liter bag size complicates this practice.
The industry is hesitant to launch such a solution, in an-
ticipation of the costly clinical trials that may be
required by the authorities. We argue that a fluid with
such a natural composition does not need extensive
clinical trials. The scientific community should re-
quest that such solutions be developed and insist that
the authorities minimize the requirements needed to
commercialize such a solution.
There are only a few indications for repeated saline ad-
ministration: metabolic alkalosis (for the high chloride
input) and hyponatremia (for the high sodium input), as
well as severe brain injury for its normotonic compos-
ition. When such conditions are not present, administra-
tion of saline solutions should usually be restricted to
not more than 1 liter per 24-h period.
Comparing two intravenous solutions with different
compositions makes no sense… unless electrolyte mea-
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